MA54860A - Méthodes de traitement du myélome multiple - Google Patents
Méthodes de traitement du myélome multipleInfo
- Publication number
- MA54860A MA54860A MA054860A MA54860A MA54860A MA 54860 A MA54860 A MA 54860A MA 054860 A MA054860 A MA 054860A MA 54860 A MA54860 A MA 54860A MA 54860 A MA54860 A MA 54860A
- Authority
- MA
- Morocco
- Prior art keywords
- multiple myeloma
- treatment methods
- myeloma treatment
- methods
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962797876P | 2019-01-28 | 2019-01-28 | |
US201962847826P | 2019-05-14 | 2019-05-14 | |
US201962861954P | 2019-06-14 | 2019-06-14 | |
US201962899094P | 2019-09-11 | 2019-09-11 | |
US201962931014P | 2019-11-05 | 2019-11-05 | |
EP19306554 | 2019-12-03 | ||
US201962943716P | 2019-12-04 | 2019-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54860A true MA54860A (fr) | 2022-05-04 |
Family
ID=69646031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054860A MA54860A (fr) | 2019-01-28 | 2020-01-28 | Méthodes de traitement du myélome multiple |
Country Status (15)
Country | Link |
---|---|
US (2) | US11939390B2 (fr) |
EP (1) | EP3917961A1 (fr) |
JP (1) | JP2022518060A (fr) |
KR (1) | KR20210120048A (fr) |
CN (1) | CN114026121A (fr) |
AU (1) | AU2020215692A1 (fr) |
BR (1) | BR112021014699A2 (fr) |
CA (1) | CA3127928A1 (fr) |
CO (1) | CO2021011034A2 (fr) |
IL (1) | IL285110A (fr) |
MA (1) | MA54860A (fr) |
MX (1) | MX2021009079A (fr) |
SG (1) | SG11202108029XA (fr) |
TW (1) | TW202043283A (fr) |
WO (1) | WO2020160020A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021009079A (es) | 2019-01-28 | 2022-02-10 | Sanofi Sa | Metodos para tratar el mieloma multiple. |
AU2020274169A1 (en) * | 2019-05-14 | 2022-01-20 | Sanofi-Aventis U.S. Llc | Methods of administering anti-CD38 antibody to treat multiple myeloma |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
EP4069743A1 (fr) * | 2019-12-05 | 2022-10-12 | Sanofi-Aventis U.S. LLC | Formulations d'anticorps anti-cd38 pour administration sous-cutanée |
TW202233235A (zh) * | 2020-11-03 | 2022-09-01 | 美商賽諾菲 安萬特美國有限責任公司 | 艾薩妥昔單抗用於治療多發性骨髓瘤的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006099875A1 (fr) * | 2005-03-23 | 2006-09-28 | Genmab A/S | Anticorps diriges contre cd38 pour le traitement du myelome multiple |
KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
CN114939119A (zh) * | 2012-08-09 | 2022-08-26 | 细胞基因公司 | 免疫相关和炎性疾病的治疗 |
US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
JP7160533B2 (ja) * | 2015-05-13 | 2022-10-25 | モルフォシス・アーゲー | 多発性骨髄腫(mm)の処置 |
JP6827426B2 (ja) | 2015-05-20 | 2021-02-10 | ヤンセン バイオテツク,インコーポレーテツド | 軽鎖アミロイドーシス及びその他のcd38陽性血液悪性疾患の治療のための抗cd38抗体 |
MX2018000265A (es) * | 2015-06-22 | 2018-05-23 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina. |
GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
SG10202105661TA (en) * | 2016-12-02 | 2021-07-29 | Rubius Therapeutics Inc | Compositions and methods related to cell systems for penetrating solid tumors |
IL271946B (en) * | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination for cancer treatment |
MX2021009079A (es) | 2019-01-28 | 2022-02-10 | Sanofi Sa | Metodos para tratar el mieloma multiple. |
-
2020
- 2020-01-28 MX MX2021009079A patent/MX2021009079A/es unknown
- 2020-01-28 WO PCT/US2020/015455 patent/WO2020160020A1/fr active Application Filing
- 2020-01-28 US US16/775,025 patent/US11939390B2/en active Active
- 2020-01-28 SG SG11202108029XA patent/SG11202108029XA/en unknown
- 2020-01-28 JP JP2021543372A patent/JP2022518060A/ja active Pending
- 2020-01-28 MA MA054860A patent/MA54860A/fr unknown
- 2020-01-28 CN CN202080024773.7A patent/CN114026121A/zh active Pending
- 2020-01-28 BR BR112021014699A patent/BR112021014699A2/pt unknown
- 2020-01-28 KR KR1020217027098A patent/KR20210120048A/ko unknown
- 2020-01-28 EP EP20706606.9A patent/EP3917961A1/fr active Pending
- 2020-01-28 AU AU2020215692A patent/AU2020215692A1/en active Pending
- 2020-01-28 CA CA3127928A patent/CA3127928A1/fr active Pending
- 2020-01-30 TW TW109102902A patent/TW202043283A/zh unknown
-
2021
- 2021-07-25 IL IL285110A patent/IL285110A/en unknown
- 2021-08-23 CO CONC2021/0011034A patent/CO2021011034A2/es unknown
-
2024
- 2024-02-16 US US18/443,878 patent/US20240190984A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200239589A1 (en) | 2020-07-30 |
WO2020160020A1 (fr) | 2020-08-06 |
TW202043283A (zh) | 2020-12-01 |
MX2021009079A (es) | 2022-02-10 |
BR112021014699A2 (pt) | 2021-11-23 |
KR20210120048A (ko) | 2021-10-06 |
JP2022518060A (ja) | 2022-03-11 |
CO2021011034A2 (es) | 2021-09-09 |
CA3127928A1 (fr) | 2020-08-06 |
EP3917961A1 (fr) | 2021-12-08 |
US11939390B2 (en) | 2024-03-26 |
SG11202108029XA (en) | 2021-08-30 |
US20240190984A1 (en) | 2024-06-13 |
CN114026121A (zh) | 2022-02-08 |
IL285110A (en) | 2021-09-30 |
AU2020215692A1 (en) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54860A (fr) | Méthodes de traitement du myélome multiple | |
MA50514A (fr) | Méthodes de traitement du myélome multiple à haut risque | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA47095A (fr) | Traitement du palais mou | |
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
MA50264A (fr) | Méthodes de traitement des infections de type hépatite b | |
MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
MA52216A (fr) | Méthodes de traitement de la colite ulcéreuse | |
MA53506A (fr) | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules | |
MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
MA53882A (fr) | Méthodes de traitement de la sclérose en plaques | |
MA47408A (fr) | Traitement du cancer | |
MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
MA52627A (fr) | Traitement du cancer | |
MA51525A (fr) | Traitement de minéraux | |
DK3856213T3 (da) | Fremgangsmåder til behandling af infektioner under anvendelse af bakterier | |
MA56033A (fr) | Méthodes de traitement de la sclérodermie généralisée | |
MA52738A (fr) | Méthodes de traitement de l'arthrite psoriasique | |
MA49688A (fr) | Procédés de traitement du syndrome myélodysplasique | |
MA53602A (fr) | Méthodes de traitement du psoriasis | |
DE112019006761A5 (de) | Desinfektionsverfahren |